PON1 and neurodevelopment in children from the chamacos study exposed to organophosphate pesticides in utero

Environmental Health Perspectives

Volumn 118, Issue 12, 2010, Pages 1775-1781

  Eskenazi, Brenda ^a   Huen, Karen ^a   Marks, Amy ^a   Harley, Kim G ^a   Bradman, Asa ^a   Barr, Dana Boyd ^b   Holland, Nina ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Biomarkers; Child behavior checklist; Children; Daps; Farmworker; Genetic susceptibility; In utero exposure; Mental development; Mexican americans; Neurodevelopment; Organophos phates; Paraoxonase; Pervasive developmental disorder; Pesticides; PON1

Indexed keywords

ALKANEDIOL DERIVATIVE; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; ORGANOPHOSPHATE PESTICIDE;

ADULT; ARTICLE; AUTISM; BAYLEY SCALE OF INFANT DEVELOPMENT; CHILD; CHILD BEHAVIOR; CHILD BEHAVIOR CHECKLIST; CHILD DEVELOPMENT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DEVELOPMENT INDEX; MUTATIONAL ANALYSIS; NERVOUS SYSTEM DEVELOPMENT; PREGNANCY; PRENATAL EXPOSURE; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOMOTOR DEVELOPMENT INDEX; RATING SCALE; UMBILICAL CORD BLOOD; URINE LEVEL;

ADOLESCENT; ADULT; ARYLDIALKYLPHOSPHATASE; BEHAVIORAL SYMPTOMS; BRAIN; CALIFORNIA; CHILD BEHAVIOR DISORDERS; CHILD DEVELOPMENT; CHILD, PRESCHOOL; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MATERNAL EXPOSURE; METABOLIC DETOXICATION, DRUG; MEXICAN AMERICANS; NUTRITION SURVEYS; ORGANOPHOSPHORUS COMPOUNDS; PESTICIDES; PREGNANCY; YOUNG ADULT;

EID: 78650262526     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1002234     Document Type: Article

References (54)

1. Achenbach T, Rescorla L. 2000. Manual for the ASEBA Preschool Forms and Profles. Burlington, VT:University of Vermont, Research Center for Children, Youth, and Families.
2. American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, Text Revision. Washington, DC:American Psychiatric Association, 943.
3. Bayley M. 1993. The Bayley Scales of Infant Development. 2nd ed. San Antonio, TX:Psychological Corporation.
4. Bradman A, Eskenazi B, Barr D, Bravo R, Castorina R, Chevrier J, et al. 2005. Organophosphate urinary metabolite levels during pregnancy and after delivery in women living in an agricultural community. Environ Health Perspect 113:1802-1807.
5. Bravo R, Driskell WJ, Whitehead RD Jr, Needham LL, Barr DB. 2002. Quantitation of dialkyl phosphate metabolites of organophosphate pesticides in human urine using GC-MS-MS with isotopic internal standards. J Anal Toxicol 26(5):245-252.
6. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. 2001. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 68(6):1428-1436.
7. Browne RO, Moyal-Segal LB, Zumsteg D, David Y, Kofman O, Berger A, et al. 2006. Coding region paraoxonase polymorphisms dictate accentuated neuronal reactions in chronic, sub-threshold pesticide exposure. FASEB J 20(10):1733-1735.
8. Caldwell B, Bradley R. 1984. Home Observation for Measurement of the Environment. Little Rock, AR:University of Arkansas.
9. California Department of Pesticide Regulation. 2005. Pesticide Use Report, Annual 2005. Sacramento, CA:California Environmental Protection Agency.
10. Chen J, Kumar M, Chan W, Berkowitz G, Wetmur JG. 2003. Increased influence of genetic variation on PON1 activity in neonates. Environ Health Perspect 111:1403-1409.
11. Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM, et al. 2003. Expression of human paraoxonase (PON1) during development. Pharmacogenetics 13(6):357-364.
12. Connelly PW, Maguire GF, Picardo CM, Teiber JF, Draganov D. 2008. Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma. J Lipid Res 49(1):245-250.
13. Costa LG, Cole TB, Vitalone A, Furlong CE. 2005. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin Chim Acta 352(1-2):37-47.
14. D'Amelio M, Ricci I, Sacco R, Liu X, D'Agruma L, Muscarella LA, et al. 2005. Paraoxonase gene variants are associated with autism in North America, but not in Italy: possible regional specificity in gene-environment interactions. Mol Psychiatry 10(11):1006-1016.
15. Dunn L, Dunn L. 1981. Peabody Picture Vocabulary Test, Revised. Circle Pines, MN:American Guidance Service.
16. Durak D, Uzun FG, Kalender S, Ogutcu A, Uzunhisarcikli M, Kalender Y. 2009. Malathion-induced oxidative stress in human erythrocytes and the protective effect of vitamins C and E in vitro. Environ Toxicol 24(3):235-242.
17. Engel SM, Berkowitz GS, Barr DB, Teitelbaum SL, Siskind J, Meisel SJ, et al. 2007. Prenatal organophosphate metabolite and organochlorine levels and performance on the Brazelton Neonatal Behavioral Assessment Scale in a multiethnic pregnancy cohort. Am J Epidemiol 165(12):1397-1404.
18. Erlich PM, Lunetta KL, Cupples LA, Huyck M, Green RC, Baldwin CT, et al. 2006. Polymorphisms in the PON gene cluster are associated with Alzheimer disease. Hum Mol Genet 15(1):77-85.
19. Eskenazi B, Bradman A, Gladstone EA, Jaramillo S, Birch K, Holland NT. 2003. CHAMACOS, a longitudinal birth cohort study: lessons from the fields. J Childrens Health 1(1):3-27.
20. Eskenazi B, Marks AR, Bradman A, Harley K, Barr DB, Johnson C, et al. 2007. Organophosphate pesticide exposure and neurodevelopment in young Mexican-American children. Environ Health Perspect 115:792-798.
21. Franco JL, Posser T, Mattos JJ, Trevisan R, Brocardo PS, Rodrigues AL, et al. 2009. Zinc reverses malathion-in-duced impairment in antioxidant defenses. Toxicol Lett 187(3):137-143.
22. Furlong CE, Holland N, Richter RJ, Bradman A, Ho A, Eskenazi B. 2006. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet Genomics 16(3):183-190.
23. Golomb BA. 2008. Acetylcholinesterase inhibitors and Gulf War illnesses. Proc Natl Acad Sci USA 105(11):4295-4300.
24. Haley RW, Billecke S, La Du BN. 1999. Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. Toxicol Appl Pharmacol 157(3):227-233.
25. Holland N, Furlong C, Bastaki M, Richter R, Bradman A, Huen K, et al. 2006. Paraoxonase polymorphisms, haplotypes, and enzyme activity in Latino mothers and newborns. Environ Health Perspect 114:985-991.
26. Huen K, Harley K, Brooks J, Hubbard A, Bradman A, Eskenazi B, et al. 2009a. Developmental changes in PON1 enzyme activity in young children and effects of PON1 polymorphisms. Environ Health Perspect 117:1632-1638.
27. Huen K, Richter R, Furlong C, Eskenazi B, Holland N. 2009b. Validation of PON1 enzyme activity assays for longitudinal studies. Clin Chim Acta 402(1-2):67-74.
28. Huen K, Harley K, Bradman A, Eskenazi B, Holland N. 2010. Longitudinal changes in PON1 enzymatic activities in Mexican-American mothers and children with different genotypes and haplotypes. Toxicol Appl Pharmacol 244(2):181-189.
29. Kafadar AM, Ergen A, Zeybek U, Agachan B, Kuday C, Isbir T. 2006. Paraoxonase 192 gene polymorphism and serum paraoxonase activity in high grade gliomas and menin-giomas. Cell Biochem Funct 24(5):455-460.
30. Kucukali CI, Aydin M, Ozkok E, Orhan N, Cakir U, Kilic G, et al. 2008. Paraoxonase-1 55/192 genotypes in schizophrenic patients and their relatives in Turkish population. Psychiatr Genet 18(6):289-294.
31. Kujiraoka T, Oka T, Ishihara M, Egashira T, Fujioka T, Saito E, et al. 2000. A sandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration. J Lipid Res 41(8):1358-1363.
32. Lawlor DA, Day IN, Gaunt TR, Hinks LJ, Timpson N, Ebrahim S, et al. 2007. The association of the paraoxonase (PON1) Q192R polymorphism with depression in older women: findings from the British Women's Heart and Health Study. J Epidemiol Community Health 61(1):85-87.
33. Leduc V, Poirier J. 2008. Polymorphisms at the paraoxonase 1 L55M and Q192R loci affect the pathophysiology of Alzheimer's disease: emphasis on the cholinergic system and beta-amyloid levels. Neurodegener Dis 5(3-4):225-227.
34. Li HL, Liu DP, Liang CC. 2003. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med 81(12):766-779.
35. Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, et al. 2000. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 10(9):767-779.
36. Mackness B, Durrington PN, Mackness MI. 2000. Low paraoxo-nase in Persian Gulf War Veterans self-reporting Gulf War syndrome. Biochem Biophys Res Commun 276(2):729-733.
37. Milatovic D, Gupta RC, Aschner M. 2006. Anticholinesterase toxicity and oxidative stress. Sci World J 6:295-310.
38. Moy SS, Nadler JJ. 2008. Advances in behavioral genetics: mouse models of autism. Mol Psychiatry 13(1):4-26.
39. Paragh G, Balla P, Katona E, Seres I, Egerhazi A, Degrell I. 2002. Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 252(2):63-67.
40. Pasca SP, Dronca E, Nemes B, Kaucsar T, Endreffy E, Iftene F, et al. 2010. Paraoxonase 1 activities and polymorphisms in autism spectrum disorders. J Cell Mol Med 14(3):600-607.
41. Pasca SP, Nemes B, Vlase L, Gagyi CE, Dronca E, Miu AC, et al. 2006. High levels of homocysteine and low serum paraoxo-nase 1 arylesterase activity in children with autism. Life Sci 78(19):2244-2248.
42. Quirós-Alcalá L. 2010. Children's Residential Exposures to Flame Retardants, Pesticides and Pesticide Degradation Products, and the Relationship of Pesticides with Autonomic Nervous System Functioning [PhD dissertation]. Berkeley, CA:University of California, Berkeley.
43. Radloff L. 1977. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1(3):385-401.
44. Richter RJ, Jarvik GP, Furlong CE. 2010. Paraoxonase 1 status as a risk factor for disease or exposure. In: Paraoxonases in Inflammation, Infection, and Toxicology (Reddy S, ed). Advances in Experimental Medicine and Biology 660. New York: Humana Press, 29-35.
45. Rojas-Garcia AE, Solis-Heredia MJ, Pina-Guzman B, Vega L, Lopez-Carrillo L, Quintanilla-Vega B. 2005. Genetic polymorphisms and activity of PON1 in a Mexican population. Toxicol Appl Pharmacol 205(3):282-289.
46. Saeed M, Siddique N, Hung WY, Usacheva E, Liu E, Suft RL, et al. 2006. Paraoxonase cluster polymorphisms are associated with sporadic ALS. Neurology 67(5):771-776.
47. Serajee FJ, Nabi R, Zhong H, Huq M. 2004. Polymorphisms in xenobiotic metabolism genes and autism. J Child Neurol 19(6):413-417.
48. Sklan EH, Lowenthal A, Korner M, Ritov Y, Landers DM, Rankinen T, et al. 2004. Acetylcholinesterase/paraoxonase genotype and expression predict anxiety scores in health, risk factors, exercise training, and genetics study. Proc Natl Acad Sci USA 101(15):5512-5517.
49. Slowik A, Tomik B, Wolkow PP, Partyka D, Turaj W, Malecki MT, et al. 2006. Paraoxonase gene polymorphisms and sporadic ALS. Neurology 67(5):766-770.
50. U.S. Census Bureau. 2000. Poverty Thresholds 2000, Current Population Survey. Washington, DC:U.S. Census Bureau.
51. Voetsch B, Benke KS, Damasceno BP, Siqueira LH, Loscalzo J. 2002. Paraoxonase 192 Gln→Arg polymorphism: an independent risk factor for nonfatal arterial ischemic stroke among young adults. Stroke 33(6):1459-1464.
52. Voetsch B, Benke KS, Panhuysen CI, Damasceno BP, Loscalzo J. 2004. The combined effect of paraoxonase promoter and coding region polymorphisms on the risk of arterial ischemic stroke among young adults. Arch Neurol 61(3):351-356.
53. Wessels D, Barr DB, Mendola P. 2003. Use of biomarkers to indicate exposure of children to organophosphate pesticides: implications for a longitudinal study of children's environmental health. Environ Health Perspect 111:1939-1946.
54. Zintzaras E, Hadjigeorgiou GM. 2004. Association of para-oxonase 1 gene polymorphisms with risk of Parkinson's disease: a meta-analysis. J Hum Genet 49(9):474-481.